nirmatrelvir and Precursor-Cell-Lymphoblastic-Leukemia-Lymphoma

nirmatrelvir has been researched along with Precursor-Cell-Lymphoblastic-Leukemia-Lymphoma* in 1 studies

Other Studies

1 other study(ies) available for nirmatrelvir and Precursor-Cell-Lymphoblastic-Leukemia-Lymphoma

ArticleYear
Successful Treatment of Prolonged, Severe Coronavirus Disease 2019 Lower Respiratory Tract Disease in a B cell Acute Lymphoblastic Leukemia Patient With an Extended Course of Remdesivir and Nirmatrelvir/Ritonavir.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023, 03-04, Volume: 76, Issue:5

    A patient with B-cell acute lymphoblastic leukemia (ALL) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had persistent, progressive pneumonia with viremia after 5 months of infection despite monoclonal antibodies, intravenous (IV) remdesivir and prolonged oral steroids. Twenty days of nirmatrelvir/ritonavir and 10 days of IV remdesivir led to full recovery.

    Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Ritonavir; SARS-CoV-2

2023